In pre-clinical pancreatic cancer models, CSF-1R signaling inhibition reduces both the numbers of tumor-infiltrating TAMs and their expression of immune-suppressive molecules and therefore acts synergistically with checkpoint inhibition (90). Here, CSF1R is linked to familial pancreatic carcinoma.